Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

被引：38
|
作者：
Garcia, Jacqueline S.
Wei, Andrew H.
Borate, Uma
Fong, Chun Yew
Baer, Maria R.
Nolte, Florian
Jurcic, Joseph G.
Jacoby, Meagan A.
Hong, Wan-Jen
Platzbecker, Uwe
Odenike, Olatoyosi
Cunningham, Ilona
Zhou, Ying
Tong, Bo
Hogdal, Leah
Kamalakar, Rajesh
Hutti, Jessica E.
Kye, Steve
Garcia-Manero, Guillermo
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139492
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination With Azacitidine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 14 - 16
  • [2] A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome
    Wei, Andrew H.
    Garcia, Jacqueline S.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Peterlin, Pierre
    Jurcic, Joseph G.
    Garcia-Manero, Guillermo
    Hong, Wan-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Dunbar, Martin
    Zhou, Ying
    Harb, Jason
    Tanwani, Poonam
    Wolff, Johannes E.
    Jacoby, Meagan
    BLOOD, 2019, 134
  • [3] Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
    Wei, Andrew H.
    Garcia, Jacqueline S.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nowak, Daniel
    Peterlin, Pierre
    Jurcic, Joseph
    Jacoby, Meagan A.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Hoffman, David
    Hogdal, Leah
    Naqvi, Kiran
    Kye, Steve
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S343
  • [4] Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naive higher-risk myelodysplastic syndromes.
    Fong, Chun Yew
    Wei, Andrew H.
    Frattini, Mark G.
    Jacoby, Meagan
    Borate, Uma
    Gotze, Katharina S.
    Garcia, Jacqueline Suen
    Pollyea, Daniel Aaron
    Holes, Leanne
    Zhou, Ying
    Fakouhi, Kaffa Mussumeh
    Leverson, Joel
    Harb, Jason G.
    Agarwal, Suresh K.
    Attarchi, Faraneh
    Mabry, Mack H.
    Hong, Wan-Jen
    Jahn, Thomas Michael
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Cook, Rachel
    Jacoby, Meagan
    Nowak, Daniel
    Chyla, Brenda
    Zhou, Ying
    Ku, Grace
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [6] A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
    Zeidan, Amer M.
    Pollyea, Daniel A.
    Garcia, Jacqueline S.
    Brunner, Andrew
    Roncolato, Fernando
    Borate, Uma
    Odenike, Olatoyosi
    Bajel, Ashish R.
    Watson, Anne Marie
    Gotze, Katharina
    Nolte, Florian
    Tan, Peter T.
    Hong, Wan-Jen
    Dunbar, Martin
    Zhou, Ying
    Gressick, Lori
    Ainsworth, William
    Harb, Jason
    Salem, Ahmed Hamed
    Hayslip, John
    Swords, Ronan
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [7] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
  • [8] Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Kishtagari, Ashwin
    Sanikommu, Srinivasa R.
    Al-Kali, Aref
    Lee, Je-Hwan
    Burgues, Juan M. Bergua
    Diez-Campelo, Maria
    Erba, Harry P.
    Garcia-Hernandez, Carmen
    Santillana, Guillermo Sanz
    O'Connell, Casey
    Jang, Jun-Ho
    Shin, Dong-Yeop
    Sayar, Hamid
    Rao, Mayank
    Schwartz, Richard S.
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Tsiatis, Athanasios C.
    Altman, Jessica K.
    CANCER RESEARCH, 2024, 84 (07)
  • [9] PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Zeidan, A. M.
    Garcia, J.
    Fenaux, P.
    Platzbecker, U.
    Miyazaki, Y.
    Xiao, Z.
    Zhou, Y.
    Naqvi, K.
    Kye, S.
    Manero, G. Garcia
    LEUKEMIA RESEARCH, 2021, 108 : S47 - S47
  • [10] The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
    Garcia, Jacqueline S.
    Wei, Andrew H.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Peterlin, Pierre
    Jurcic, Joseph
    Jacoby, Meagan
    Hong, Wen-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Dunbar, Martin
    Harb, Jason G.
    Popovic, Relja
    Tanwani, Poonam
    Gopalakrishnan, Sathej
    Wolff, Johannes
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S315 - S316
12345